Assessment Status | NCPE Assessment Process Complete |
HTA ID | - |
Drug | Dimethyl fumarate |
Brand | Tecfidera® |
Indication | For the treatment of adult patients with relapsing remitting multiple sclerosis (MS) |
Assessment Process | |
Rapid review commissioned | 04/02/2014 |
Rapid review completed | 06/03/2014 |
Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
Full submission received from Applicant | 16/07/2014 |
NCPE assessment completed | 14/01/2015 |
NCPE assessment outcome | Reimbursement not recommended |
14/04/2015
Following pricing negotiation, the HSE has approved reimbursement of Tecfidera® under the High Tech Drugs Scheme.